Inovio announces orphan drug designation for ino-3107 for the treatment of recurrent respiratory papillomatosis from the european commission

Plymouth meeting, pa. , may 23, 2023 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that the european commission (ec) has granted orphan drug designation for ino-3107, the company's product candidate for the treatment of recurrent respiratory papillomatosis (rrp).
INO Ratings Summary
INO Quant Ranking